誉衡药业
(002437)
| 流通市值：76.75亿 | | | 总市值：81.39亿 |
| 流通股本：21.03亿 | | | 总股本：22.30亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,007,061,544.15 | 539,105,711.33 | 2,135,451,494.88 | 1,664,997,338.49 |
| 营业总成本 | 854,148,219.96 | 463,882,978.06 | 1,906,201,168.54 | 1,463,760,914.56 |
| 其他经营收益 | | | | |
| 营业利润 | 183,528,630.5 | 107,268,905.61 | 404,911,016.92 | 265,253,964.82 |
| 利润总额 | 183,386,721.16 | 107,129,960.84 | 409,616,937.61 | 269,333,326 |
| 净利润 | 162,333,510.27 | 96,667,211.33 | 382,357,127.75 | 247,923,573.93 |
| 每股收益 | | | | |
| 其他综合收益 | -2,275,845.63 | -1,530,963.76 | -1,098,908.06 | -639,692.29 |
| 综合收益总额 | 160,057,664.64 | 95,136,247.57 | 381,258,219.69 | 247,283,881.64 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,405,427,295.93 | 1,349,111,397.17 | 1,318,845,985.97 | 1,149,038,353.7 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,856,676,041.06 | 1,792,484,158.63 | 1,815,731,813.98 | 1,880,921,737.96 |
| 资产总计 | 3,262,103,336.99 | 3,141,595,555.8 | 3,134,577,799.95 | 3,029,960,091.66 |
| 流动负债: | | | | |
| 流动负债合计 | 746,030,720.22 | 709,563,333.96 | 797,849,403.68 | 825,780,524.56 |
| 非流动负债: | | | | |
| 非流动负债合计 | 25,918,415.99 | 26,395,220.23 | 27,154,017.78 | 26,399,808.85 |
| 负债合计 | 771,949,136.21 | 735,958,554.19 | 825,003,421.46 | 852,180,333.41 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,470,903,307.78 | 2,387,993,475.44 | 2,293,671,990.18 | 2,157,141,926.53 |
| 股东权益合计 | 2,490,154,200.78 | 2,405,637,001.61 | 2,309,574,378.49 | 2,177,779,758.25 |
| 负债和股东权益合计 | 3,262,103,336.99 | 3,141,595,555.8 | 3,134,577,799.95 | 3,029,960,091.66 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,145,170,914.47 | 584,768,616.12 | 2,479,951,968.01 | 1,936,541,711.79 |
| 经营活动现金流出小计 | 963,010,256.84 | 512,058,326.84 | 2,206,596,454.54 | 1,628,276,851.38 |
| 经营活动产生的现金流量净额 | 182,160,657.63 | 72,710,289.28 | 273,355,513.47 | 308,264,860.41 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 650,711,540.99 | 447,631,423.67 | 1,321,760,890.23 | 979,014,562.57 |
| 投资活动现金流出小计 | 724,967,028.94 | 179,282,920.31 | 1,654,113,698.98 | 1,307,839,226.98 |
| 投资活动产生的现金流量净额 | -74,255,487.95 | 268,348,503.36 | -332,352,808.75 | -328,824,664.41 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 67,319,650 | - | 90,000,000 | 70,000,000 |
| 筹资活动现金流出小计 | 74,061,887.55 | 73,543,343.06 | 114,050,434.38 | 90,260,190.15 |
| 筹资活动产生的现金流量净额 | -6,742,237.55 | -73,543,343.06 | -24,050,434.38 | -20,260,190.15 |
| 汇率变动对现金及现金等价物的影响 | -2,859,825.3 | -1,436,780.01 | -1,887,808.59 | -968,043.41 |
| 现金及现金等价物净增加额 | 98,303,106.83 | 266,078,669.57 | -84,935,538.25 | -41,788,037.56 |
| 期末现金及现金等价物余额 | 494,140,259.03 | 661,907,577.33 | 395,837,152.2 | 438,984,652.89 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 98,303,106.83 | - | -84,935,538.25 | - |